(CercleFinance.com) – The biotechnology company Abivax publishes a net loss of 52 million euros for the first half of 2023, compared to a loss of 21.2 million a year earlier, with an operating profit falling from -26 to -37.3 million year over year.
Revenues from the Research Tax Credit remained stable at 2.3 million euros, while R&D expenses, mainly linked to the development of obefazimod in inflammatory indications, increased to 32.6 million.
Cash at June 30, 2023 amounted to 114.4 million euros, compared to 27 million at the end of 2022. ‘In 2023, we successfully completed equity financing of 130 million euros’, recalls the financial director Didier Blondel.